MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
IVVD stock logo

IVVD

Invivyd, Inc.

$0.99
-0.03
 (-2.94%)
Exchange:  NASDAQ
Market Cap:  131.402M
Shares Outstanding:  111.246M
Delayed data
Calculate IVVD Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  William E. Duke Jr.
Full Time Employees:  99
Address: 
1601 Trapelo Road
Waltham
MA
2451
US
Website:  https://adagiotx.com
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company’s leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company’s base of operations is in Waltham, Massachusetts.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/15 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue025,38453,426
Gross Profit023,76649,679
EBITDA-205,755-173,763-53,453
Operating Income-212,758-176,876-55,560
Net Income-198,643-169,925-52,489

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets229,181129,515276,883
Total Liabilities51,71361,97635,343
Total Stockholders Equity177,46867,539241,540
Total Debt2,1651,3042,494
Cash and Cash Equivalents200,64169,349226,689

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-173,164-170,491-58,135
Capital Expenditure-615-140-155
Free Cash Flow-173,779-170,631-58,290
Net Income-198,643-169,925-52,489
Net Change in Cash108,565-131,292157,340

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)664,645.644Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)849,707.721Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)771,650Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)132,929.128Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)169,941.544Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)154,329.999Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)115,051.996Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)158,811.294Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)140,353.515Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)897,264.057Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,147,095.755Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,041,718.720Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.820Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.920Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.670Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
2.45
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-4.11
?Enterprise Value
 (TTM)
: 
-38815675  ?EV/FCF
 (TTM)
: 
0.49
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.53  ?ROIC
 (TTM)
: 
-0.39
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.04
?P/B
 (TTM)
: 
1.57  ?Current Ratio
 (TTM)
: 
6.47

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about IVVD valuation

Is Invivyd, Inc. (IVVD) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Invivyd, Inc. (IVVD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is IVVD a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IVVD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is IVVD’s P/E ratio?

You can see IVVD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for IVVD?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is IVVD a good long-term investment?

Whether IVVD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

IVVD

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.94
MARKETSnap

Trading Metrics:

Open: 1.03   Previous Close: 1.02
Day Low: 0.97   Day High: 1.05
Year Low: 0.48   Year High: 3.07
Price Avg 50: 1.36   Price Avg 200: 1.7
Volume: 5.389M   Average Volume: 3.069M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for IVVD

Relevant news

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
14-05-2026 09:16
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript
09-04-2026 19:42
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript
Invivyd Announces Presentation at the World Vaccine Congress Washington
30-03-2026 16:05
Invivyd Announces Presentation at the World Vaccine Congress Washington
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
02-03-2026 16:10
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read